Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer
Studies Shed Light On Racial Disparities Between Blacks, Whites With Breast Cancer
Shorter, Simpler Consent Form Proposed For Phase I Trials
How Much Is Life Worth? The $440 Billion Question
Sunitinib Prolongs Survival In Poor Prognosis, Study Finds
Breast MRI Recipients More Likely To Choose Mastectomy
Opioid Pain Reliever Approved With Risk Reduction Plan
NCI Cooperative Group Clinical Trials Approved
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds
- A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. - Did peer review fail? Nature Medicine’s chronotherapy paper retraction raises questions
- A new diagnostic lens—and a lasting scientific legacy
- OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill









